Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβ

Clinical Cancer Research

Volumn 11, Issue 23, 2005, Pages 8467-8475

  Marchion, Douglas C ^a   Bicaku, Elona ^a   Turner, Joel G ^a   Daud, Adil I ^a   Sullivan, Daniel M ^a   Munster, Pamela N ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; EPIRUBICIN; GYRASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MITOXANTRONE; SMALL INTERFERING RNA; TENIPOSIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; XK 469;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CHROMATIN CONDENSATION; COMPLEX FORMATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIZATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BUTYRATES; CHROMATIN; DNA TOPOISOMERASES, TYPE II; DNA, ANTISENSE; DNA-BINDING PROTEINS; DRUG INTERACTIONS; DRUG SYNERGISM; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MITOXANTRONE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, SMALL INTERFERING; TENIPOSIDE; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 28544432910     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1073     Document Type: Article

References (50)

1. Lang AJ, Mirski SE, Cummings HJ, et al. Structural organization of the human TOP2A and TOP2B genes. Gene 1998;221:255-66.
2. Drake FH, Hofmann GA, Bartus HF, et al. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989;28: 8154-60.
3. Larsen AK, Skladanowski A, Bojanowski K. The roles of DNA topoisomerase II during the cell cycle. Prog Cell Cycle Res 1996;2:229-39.
4. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:139-54.
5. Heck MM, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci U S A 1988; 85:1086-90.
6. Prosperi E, Sala E, Negri C, et al. Topoisomerase II α and β in human tumor cells grown in vitro and in vivo. Anticancer Res 1992;12:2093-9.
7. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991;2:209-14.
8. Xiao H, Mao Y, Desai SD, et al. The topoisomerase IIβ circular clamp arrests transcription and signals a 26S proteasome pathway. Proc Natl Acad Sci U S A 2003;100:3239-44.
9. Sakaguchi A, Kikuchi A. Functional compatibility between isoform α and β of type II DNA topoisomerase. J Cell Sci 2004;117:1047-54.
10. Berger JM, Gamblin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature 1996;379:225-32.
11. Capranico G, Tinelli S, Zunino F. Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells. Chem Biol Interact 1989;72:113-23.
12. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:83-105.
13. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIα associate with ErbB- 2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47.
14. Marchion DC, Bicaku E, Daud AI, et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004;92:223-37.
15. Gudkov AV, Zelnick CR, Kazarov AR, et al. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A 1993;90:3231-5.
16. Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES. Transfection of human topoisomerase II α into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 1996;319:307-13.
17. MacGrogan G, Rudolph P, Mascarel Id I, et al. DNA topoisomerase Ha expression and the response toprimary chemotherapy in breast cancer. Br J Cancer 2003;89:666-71.
18. Tsai SC, Valkov N, Yang WM, et al. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000;26:349-53.
19. Kim MS, Blake M, Baek JH, et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-300.
20. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Valpraic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005;65:3815-22.
21. Towatari M, Adachi K, Marunouchi T, Saito H. Evidence for a critical role of DNA topoisomerase IIα in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line. Br J Haematol 1998;101:548-51.
22. Willmore E, Frank AJ, Padget K, Tilby MJ, Austin CA. Etoposide targets topoisomerase IIα and IIβ in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol 1998;54: 78-85.
23. Munster PN, Troso-Sandoval T, Rosen N, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-7.
24. Qiu J, Catapano CV, Fernandes DJ. Formation of topoisomerase II α complexes with nascent DNA is related to VM-26-induced cytotoxicity. Biochemistry 1996;35:16354-60.
25. Christensen MO, Larsen MK, Barthelmes HU, et al. Dynamics of human DNA topoisomerases IIα and IIβ in living cells. J Cell Biol 2002;157:31-44.
26. Null AP, Hudson J, Gorbsky GJ. Both α and β isoforms of mammalian DNA topoisomerase II associate with chromosomes in mitosis. Cell Growth Differ 2002;13:325-33.
27. Marsh KL, Willmore E, Tinelli S, et al. Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms α and β. Biochem Pharmacol 1996;52:1675-85.
28. Austin CA, Marsh KL. Eukaryotic DNA topoisomerase II β. Bioessays 1998;20:215-26.
29. Jensen S, Redwood CS, Jenkins JR, Andersen AH, Hickson ID. Human DNA topoisomerases II α and II β can functionally substitute for yeast TOP2 in chromosome segregation and recombination. Mol Gen Genet 1996;252:79-86.
30. Yang X, Li W, Prescott ED, Burden SJ, Wang JC. DNA topoisomerase IIβ and neural development. Science 2000;287:131-4.
31. Akimitsu N, Kamura K, Tone S, et al. Induction of apoptosis by depletion of DNA topoisomerase IIα in mammalian cells. Biochem Biophys Res Commun 2003;307:301-7.
32. Grue P, Grasser A, Sehested M, et al. Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells. J Biol Chem 1998;273:33660-6.
33. Corbett AH, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 1993;6: 585-97.
34. Jensen LH, Wessel I, Moller M, et al. N-terminal and core-domain random mutations in human topoisomerase II α conferring bisdioxopiperazine resistance. FEBS Lett 2000;480:201-7.
35. Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Incidence of mutation and deletion in topoisomerase II α mRNA of etoposide and mAMSA-resistant cell lines. Jpn J Cancer Res 2001;92:1133-7.
36. Kruczynski A, Barret JM, Van Hille B, et al. Decreased nucleotide excision repair activity and alterations of topoisomerase IIα are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II. Clin Cancer Res 2004;10:3156-68.
37. Kellner U, Rudolph P, Parwaresch R. Human DNA-topoisomerases: diagnostic and therapeutic implications for cancer. Onkologie 2000;23:424-30.
38. Johnson CA, Padget K, Austin CA, Turner BM. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J Biol Chem 2001;276:4539-42.
39. Niitsu N, Kasukabe T, Yokoyama A, et al. Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol Pharmacol 2000;58: 27-36.
40. Kurz EU, Wilson SE, Leader KB, et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II α expression and confers hypersensitivity to etoposide in human leukemic cell lines. Molecular Cancer Therapeutics 2002;1:121-31.
41. Fraser DJ, Brandt TL, Kroll DJ. Topoisomerase II α promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells. Mol Pharmacol 1995;47:696-706.
42. Cuvier O, Hirano T. A role of topoisomerase II in linking DNA replication to chromosome condensation. J Cell Biol 2003;160:645-55.
43. Mensah-Osman EJ, Al-Katib AM, Dandashi MH, Mohammad RM. 2-[4-(7-chloro-2-quinoxalinyloxy)-phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIβ is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model. Mol Cancer Ther 2002;1:1315-20.
44. Errington F, Willmore E, Tilby MJ, et al. Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol 1999;56:1309-16.
45. Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II β isoform. Biochemistry 1991;30:9953-61.
46. Gao H, Huang KC, Yamasaki EF, et al. XK469, a selective topoisomerase IIβ poison. Proc Natl Acad Sci U S A 1999;96:12168-73.
47. Feldhoff PW, Mirski SE, Cole SP, Sullivan DM. Altered subcellular distribution of topoisomerase II α in a drug-resistant human small cell lung cancer cell line. Cancer Res 1994;54:756-62.
48. Beck WT, Danks MK, Wolverton JS, Kim R, Chen M. Drug resistance associated with altered DNA topoisomerase II. Adv Enzyme Regul 1993;33:113-27.
49. Nitiss JL, Liu YX, Hsiung Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 1993;53:89-93.
50. Kobayashi M, Adachi N, Aratani Y, Kikuchi A, Koyama H. Decreased topoisomerase IIα expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells. Cancer Lett 2001;166:71-7.